Obermatt
See Similar Stocks →

Flags

Financial distress

Immunitybio

NSQ:IBRX · US45256X1037
BiotechnologySmall

360

19
Profit price44
Cash yield1
Price/Sales39
EV / Gross Profit13
Price/Book89
Returns on capital4
EBIT Margin8
Gross Profitability49
Accruals97
Owner Earnings Margin21
Sales growth78
Profit growth93
Reinvestment53
Price momentum72
Debt load3
Refinancing95
Debt Payback1
Liquidity85
Analyst ratings36
Opinion Changes5
Price Target Upside94
Market mood33
Value Creation7/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Immunitybio clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Employees522
Websiteimmunitybio.com
ISINUS45256X1037
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyInfectious DiseasesVaccinesOncologyHealth Care

Description

ImmunityBio, Inc. (ImmunityBio) is a biotechnology company. The company focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against ca…

Analysis

Hope premium

ImmunityBio, Inc. is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 7/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
39
—
—
—
Price/Earnings
100
—
—
—
Price/Book
89
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
100
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Immunitybio with its peers
Eledon Pharmaceuticals
NAQ:ELDN
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Coeptis Therapeutics
NAQ:COEP
27
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
MeiraGTx
NSQ:MGTX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kura Oncology
NSQ:KURA
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vera Therapeutics
NMQ:VERA
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kyverna Therapeutics
NSQ:KYTX
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →